Human medicines European public assessment report (EPAR): Vyxeos liposomal (previously known as Vyxeos), daunorubicin,cytarabine, Leukemia, Myeloid, Acute, Date of authorisation: 23/08/2018, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Vyxeos liposomal (previously known as Vyxeos), daunorubicin,cytarabine, Leukemia, Myeloid, Acute, Date of authorisation: 23/08/2018, Revision: 9, Status: Authorised